This is an enormous opportunity, and Lilly's clinical pipeline looks well positioned. Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now ...
One of the highlights of Eli Lilly's third-quarter results was the rapid uptake of new type 2 diabetes therapy Mounjaro, which added more than $97 million in US sales alone in what has been ...
Eli Lilly’s expectations for sales in the fourth quarter of last year missed forecasts, driven by lower-than-expected sales of its diabetes and obesity drugs Mounjaro and Zepbound. This is ...
Eli Lilly can’t seem to recover from its GLP-1 stumble. Once again, the drugmaker reported sales of its blockbuster GLP-1 medicines Zepbound and Mounjaro that missed Wall Street estimates.
Reports indicate he was actually taking Eli Lilly's (NYSE: LLY) weight-loss drug Mounjaro. Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon ...
Let's see if the momentum can continue. While Ozempic has more brand recognition, Eli Lilly's Mounjaro and Zepbound have proven better clinically at helping patients lose weight. The two Eli Lilly ...